Table 1.

Summary of CFRD patients with significant changes in blood glucose and diabetes management after institution of ivacaftor.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age at CF diagnosis	2 years	5 years	5 weeks	8 years	2 years
Mutations	Δ508/G551D	Δ508	Δ508	Δ508	Δ508/S549R
Age at CFRD diagnosis	20	29	16	30	20
Age at ivacaftor initiation	28	30	29	32	29
Specific drug	ivacaftor	combined**	combined	combined	ivacaftor
Time to CFRD resolution	9 months	1 month	8 months	12 months	12 months*
Continued hypoglycemia	Yes	Yes	No	No	Yes
Follow up post CFRD resolution	5 years	1 year	8 months	2 years	4 years*
Change in FEV1 (% predicted)	ND***	+3%	+3%	+13%	+8%
Change in BMI	ND	−1.0	+1.5	+0.7	0

^*Patient had reduction in insulin use from short-acting insulin three times a day to once a week, not complete resolution

^**lumacaftor/ivacaftor combination drug

^***ND = no data